Problems in humans have not been documented {01}.
Safety and efficacy have not been established {01}
in patients up to 18 years of age. If covering is
needed, patient should use nonocclusive material,
such as cotton gauze or cotton underclothes. Patient
should wash hands before and after administration to
help avoid translocation of cream, especially to
eyes, and should wash the treatment area thoroughly
with mild soap and water before engaging in sexual
activities. Also, oils in the cream can weaken latex
contraceptive devices, such as cervical caps,
condoms, and diaphragms, and reduce their aldara
drug used.
Of the remaining 50% of
patients, 33% still had genital warts at 16 weeks
and 17% withdrew from the clinical trial {01}. Of
those who had complete wart clearance at 10 weeks
and could be followed for 12 additional weeks, 23%
of patients remained wartfree {01}. Problems in
humans have not been documented. Maternotoxicity,
but not teratogenicity, as shown by reduced pup
weights and delayed ossification, occurred in
studies of female
rats given doses 28
times the aldara drug used human dose (based on mg
per aldara drug used meter of body surface area). In
developmental studies, no adverse effects appeared
in the offspring of pregnant rats who received eight
times the recommended human dose {01}.
Imiquimod is not a cure and new warts may develop
during treatment; effect of imiquimod on
transmission of genital warts is not known.
Imiquimod
aldara
capsules not have direct antiviral activity.
Studies of mice show that imiquimod may induce
cytokines, including interferonalpha, in mouse skin;
clinical significance or relevance of this finding
to humans is not known. Imiquimod potentially can
exacerbate inflammatory conditions of the skin {01}.
In one clinical trial that had a 4 to 6 ratio of
females to males, 50% of patients,
aldara
drug review 75% of females and 33% of males,
experienced complete wart clearance after using
imiquimod for 10 weeks (median, range 4 to 16
weeks).
When experiencing any discomfort
or if severe reaction aldara drug used, patient
should delay next dose for several days, and report
severe local skin reactions and rare systemic
reactions to physician. Using nonocclusive dressing,
such as
gauze, or cotton
underclothes to help manage skin reactions {01}.
Treatment is continued until wart is gone or for up
to sixteen weeks. Protect from freezing. This
material is provided for educational purposes only
and is not to be used for medical advice, diagnosis
or treatment.
To view content sources and
attributions, refer to our editorial policy. All
rights reserved.
